# Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR Study

> **NCT03832673** · PHASE2 · WITHDRAWN · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano**

## Conditions studied

- Muscle-invasive Bladder Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Epacadostat

## Key facts

- **NCT ID:** NCT03832673
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-05-22
- **Primary completion:** 2019-05-22
- **Final completion:** 2019-05-22
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Regolatory National Agency (AIFA) not approved
- **Last updated:** 2021-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03832673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03832673, "Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR Study". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT03832673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*